ETNB - 89bio, Inc.

NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
+0.95 (+5.50%)
收市:04:00PM EDT
18.25 +0.02 (+0.11%)
收市後: 06:41PM EDT
買盤0.00 x 800
賣出價0.00 x 800
今日波幅17.03 - 18.35
52 週波幅2.91 - 18.92
Beta 值 (5 年,每月)0.77
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-2.31
業績公佈日2023年8月09日 - 2023年8月14日
遠期股息及收益率無 (無)
1 年預測目標價35.13
  • Insider Monkey

    12 Best Biotech Stocks To Buy Under $20

    In this piece, we will take a look at the 12 best biotechnology stocks to buy under $20. For more stocks, head on over to 5 Best Biotech Stocks To Buy Under $20. The biotechnology industry is one of the hottest sectors right now, particularly in the aftermath of the coronavirus pandemic since it was […]

  • Insider Monkey

    10 Best Biotech Stocks Under $10

    In this article, we will look at the 10 best biotech stocks under $10. If you want to explore similar biotech stocks with promising prospects that you can get for under $10, you can also take a look at 5 Best Biotech Stocks Under $10. The Global Biotech Industry According to an industry analysis report […]

  • Benzinga

    89bio's Pegozafermin Data Shows Improved Liver Fat, Glycemic Control

    89bio Inc (NASDAQ: ETNB) announced the presentation of data from the ENTRIGUE Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia (SHTG) at the European Society of Cardiology Congress. Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, increasing the risk of coronary artery disease. Pegozafermin met its primary endpoint of statistically significant reductions in median triglycerides (TGs) from baseline across all dose

  • Benzinga

    This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations

    In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG). SVB Leerink views these results as 'strong' and says they provide a clear win for the company as all doses of pegoza demonstrated statistically significant and clinically meaningful reductions in triglycerides, exceeding KOL expectations ahead of the results. The analysts say that pegoza's safety/tolerability profile continues to loo